Climb Bio, Inc. (CLYM) Stock Ticker
CLYM right now
Market factors today
Unlock the full CLYM picture
About Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM stock facts
| Ticker symbol | CLYM |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $667.7M |
| CEO | Aoife Brennan BCh MMSc |
| Employees | 28 |
| Headquarters | Wellesley Hills, MA, US |
| IPO date | 2021-08-10 |
| Website | climbbio.com |
What you can see for CLYM on Tickr
Live CLYM price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CLYM report.
Rankings
FAQ
What is the ticker symbol for Climb Bio, Inc.?
The ticker symbol for Climb Bio, Inc. is CLYM, listed on the NASDAQ Global Market.
What is CLYM?
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous…